By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

GSK and UK-based rival AstraZeneca have revealed billions of dollars in US investment in recent months in response to ...

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ...

hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives ...

Preview this article 1 min Madrigal Pharmaceuticals is moving to a new 54,000-square-foot headquarters as its workforce nears ...

Ohio-based Welltower acquired adjacent senior housing centers for a total of $140M, the Boston Business Journal reported. The ...

GSK has now taken over the entirety of 200 CambridgePark Drive, a six-story building that will eventually house about 400 ...

Former Nimbus Therapeutics CEO brings proven expertise scaling platform biotech companies and executing key strategic partnerships as Strand advances its clinical pipeline. BOSTON ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...